|
|
|
Friday, 21 November 2008 |
Depomed to discuss license agreement with Solvay
|
|
Thursday, 20 November 2008 |
ACRUX Testosterone MD-Lotion(R) phase III trial enrolment halfway completed
|
|
Thursday, 20 November 2008 |
SurModics to restructure, initiate cost-cutting measures
|
|
Tuesday, 18 November 2008 |
Orphan-drug designations given to Delcath's melphalan for cutaneous and ocular melanoma
|
|
Tuesday, 18 November 2008 |
CHMP recommends for approval IDM Pharma's drug mifamurtide for osteosarcoma
|
|
Monday, 17 November 2008 |
Capsulution and NanoDel merge
|
|
Saturday, 15 November 2008 |
Biodel announces positive effects of VIAject(TM) Insulin on type 2 diabetes
|
|
Friday, 14 November 2008 |
Results presented for Oramed Pharmaceuticals canine study of orally administered exenatide-4
|
|
Wednesday, 12 November 2008 |
OctoPlus and Biolex therapeutics in new drug delivery evaluation agreement
|
|
Tuesday, 11 November 2008 |
Etna Biotech, a subsidiary of Crucell N.V., bought by Zydus Cadila
|
|
Monday, 10 November 2008 |
Amylin anticipates $80 million less in costs after strategic restructuring and workforce whittling
|
|
Friday, 07 November 2008 |
BioDelivery Sciences to present ONSOLIS(TM) REMS to FDA
|
|
Thursday, 06 November 2008 |
Six European countries approve Diamyd Medical's Diamyd(R) phase III study
|
|
Wednesday, 05 November 2008 |
Generex Biotechnology products submitted for Syrian registration
|
|
Wednesday, 05 November 2008 |
Additional regulatory approvals for Antares Pharma's needle-free injection device
|
|
Tuesday, 04 November 2008 |
SurModics: PR Pharmaceuticals drug delivery assets broaden company portfolio
|
|
Monday, 03 November 2008 |
Data set closed for Cell Therapeutics - Novartis phase III pivotal pixantrone trial
|
|
Saturday, 01 November 2008 |
Study shows Paliperidone ER may significantly improve schizoaffective disorder symptoms
|
|
Friday, 31 October 2008 |
Celldex well tolerated phase I studies of CDX-1307 presented at the iSBTc meeting
|
|
Thursday, 30 October 2008 |
SurModics to provide hydrophilic coating for Elixir's DES
|
|
Wednesday, 29 October 2008 |
Additional time to complete NDA review for Cipher's tramadol
|
|
Wednesday, 29 October 2008 |
DURECT Alpharma collaboration OKed by HSR Review
|
|
Tuesday, 28 October 2008 |
Encouraging data from QLT's phase II study of punctal plug drug delivery system
|
|
Monday, 27 October 2008 |
Nano Bio presents data for two studies
|
|
Friday, 24 October 2008 |
Acusphere signs definitive agreement with Cephalon
|
|
Thursday, 23 October 2008 |
Aradigm phase II data on inhaled cystic fibrosis treatment presented
|
|
Thursday, 23 October 2008 |
Columbia Laboratories and NIH to collaborate on a short cervix study
|
|
Thursday, 23 October 2008 |
SkyePharma successfully completes Flutiform(TM) U.S. clinical trial program
|
|
Wednesday, 22 October 2008 |
MDRNA acquires intellectual property rights to UNA technology
|
|
Tuesday, 21 October 2008 |
Oral salmon calcitonin for osteoarthritis to be tested in Emisphere's second phase III trial
|
|
Tuesday, 21 October 2008 |
Nektar to sell Novartis part of its pulmonary holdings; while retaining a portion of same
|
|
Tuesday, 21 October 2008 |
NovaDel finalizes $2,525,000 Financing agreement with ProQuest investments
|
|
Tuesday, 21 October 2008 |
ULURU announces start of first clinical study of Altrazeal(TM) silver in wound healing
|
|
Monday, 20 October 2008 |
Depomed starts Breeze 1 and 2 phase III trials in menopausal hot flashes
|
|
Monday, 20 October 2008 |
ADVENTRX restructures in cost cutting initiative
|
|
Monday, 20 October 2008 |
QLT announces drop in 3rd quarter Visudine(R) sales
|
|
Friday, 17 October 2008 |
Ichor TriGrid phase I safety data for preventive HIV vaccine to be presented at AIDS conference
|
|
Friday, 17 October 2008 |
Neose Technologies' common stock listed on Nasdaq pending appeal hearing
|
|
Thursday, 16 October 2008 |
Abraxis BioScience to market ABRAXANE(R) in Australia
|
|
Thursday, 16 October 2008 |
Alexza's enrollment for second AZ-004 phase III trial completed
|
|
Thursday, 16 October 2008 |
Generex Announces metformin gum trial initial subject enrollment
|
|
Wednesday, 15 October 2008 |
UMMS grants RXi Pharmaceuticals exclusive worldwide licensing for oral delivery RNAi therapeutics
|
|
Tuesday, 14 October 2008 |
Aradigm's phase II enrollment for study of inhaled ciprofloxacin for bronchiectasis completed
|
|
Tuesday, 14 October 2008 |
Orally administered salmon calcitonin more effective than nasal
|
|
Sunday, 12 October 2008 |
FDA approves second generation TAXUS(R) Liberte(R) DES
|
|
Friday, 10 October 2008 |
ABLYNX R&D update announces successful generation of Nanobodies(R) against GPCRs
|
|
Friday, 10 October 2008 |
AstraZeneca receives FDA approval for SEROQUEL XR(R) in bipolar treatment
|
|
Thursday, 09 October 2008 |
Archimedes Pharma announces positive phase III clinical trial results for NasalFent(R)
|
|
Thursday, 09 October 2008 |
New injection site for RISPERDAL(R) CONSTA(R)
|
|
Thursday, 09 October 2008 |
Phase I trial of QLT synthetic retinoid product begins
|
| |
|
Results 1 - 50 of 118 |
